

ENDPOINTS NEWS


BIOPHARMA JOBS

MORE

Search

Ana Mulero

In an effort to get the first set of FY 2019 appropriations bills to the President’s desk, US House leaders scrapped a bipartisan amendment that would have required drugmakers to include list prices in direct-to-consumer (DTC) television ads.



Chuck Grassley

The amendment — sponsored by Sens. Dick Durbin (D-IL) and Chuck Grassley (R-IA) — was offered and subsequently withdrawn during a joint conference committee of the House and Senate, despite **passing** the Senate last month. The move was followed by finger pointing.



ChuckGrassley 
@ChuckGrassley



Hearing rumors my bipartisan Durbin/Grassley legis to make drug companies list prices on TV ads is out of spending bill It is EMBARRASSING to bow to BIG PHARMA at expense of consumers Policy is supported by Pres Trump+AARP+Dem&GOP Sens If we can agree why are lobbyists fighting?

11:30 AM · Sep 13, 2018



 1.2K  456  Share this Tweet

CHANNELS



ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Search

“Transparency in advertising is the very least Congress can do,” Durbin added.

Durbin took to Twitter after the joint hearing, citing “Big Pharma and their representatives in Congress” as the “only group who opposed” the amendment.




Senator Dick Durbin · Sep 13, 2018



@SenatorDurbin

My amendment with @ChuckGrassley & @SenAngusKing was supported by both parties, @AARP, American Medical Association, health insurance plans, 76% of Americans, Pres Trump & HHS. The only group who opposed it? Big Pharma & their Representatives in Congress:



House GOP blocks Trump-supported drug pricing provision from spending

thehill.com



Senator Dick Durbin

@SenatorDurbin

The #1 driver for increases in premiums are Rx drugs & TV drug ads inflate drug

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Amendment Comments

The Durbin-Grassley amendment, which was not included in the draft funding bill that was [released](#) in June, did not make it through the negotiation agreement because to “too many of our friends across the table here, it was controversial,” Sen. Richard Shelby (R-AL) said.

Sen. Patrick Leahy (D-VT) echoed Shelby’s comments and concerns during the joint hearing.

The fact that it is a Durbin-Grassley amendment that the Senate already passed “speaks to how worthwhile it is” and “people ought to know” how much prescription drugs are going to cost in DTC advertisements, said Leahy. In the interest of returning to regular order, Leahy ultimately sided with Shelby in opposition to including the amendment in the joint conference report.

Durbin and Grassley expressed disappointment with the decision to drop the proposal for now at least, arguing against the characterization of the amendment as a “poison pill rider.”

It was removed “in a last-minute, backroom deal,” Grassley [said](#), pointing to those that had showed support. These include the [American Hospital Association](#), the [Federation of American Hospitals](#) and the [Campaign for Sustainable Rx Pricing \(CSRxP\)](#), among several others.

The bill “abandons the real bipartisan progress the Senate and the Trump Administration made to hold Big Pharma accountable for out-of-control drug prices and give patients the information they need to make smart decisions about their health

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

from seeking care.”

First published [here](#). Regulatory Focus is the flagship online publication of the Regulatory Affairs Professionals Society (RAPS), the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Email news@raps.org for more information.

AUTHOR

Ana Mulero

info@raps.org

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Search



Australia's Avance Clinical: no IND required and a 43.5% rebate on clinical spend for CGT biotechs

SPONSORED

November 22, 2021 06:00 AM EST

No IND Required for Cell and Gene Therapy Studies with Australia's Accredited CRO Avance Clinical

Meridee Arthur

Principal Scientific & Regulatory Affairs Specialist, Principal GCP Advisor

Avance Clinical is the specialist Australian CRO, with CGT accreditation, for international biotechs that leverages Australia's supportive clinical trials environment

which includes no IND requirement plus a 43.5% Government incentive rebate on clinical spend.

Learn more about Avance ClinicReady here.

Contact us about your next study.

Download our Frost & Sullivan APAC CRO Report here.

The cell and gene therapies (CGT) sector offers unprecedented opportunities for

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Search



Ursula von der Leyen, President of the European Commission

November 26, 2021 07:06 AM EST

Updated 05:32 PM

Coronavirus

Omicron: Researchers scramble as new coronavirus mutation takes flight around the globe — Pfizer/BioN-Tech, Moderna vow swift response

John Carroll

Editor & Founder

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE



November 27, 2021 06:00 AM EST

Weekly

Thanksgiving edition: Top 15 Endpoints stories of 2021; Can you name that vaccine?; Merck's Covid antiviral disappoints; FDA nominee's industry ties; and more

Amber Tong

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE 

ENDPOINTS NEWS

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

[SIGN UP](#)

[LOG IN](#)

ENDPOINTS CAREERS

Lead Manager / Associate Director of Statistical Genetics

Deep Genomics
Boston, MA, USA

[VIEW JOB OFFER](#)

post your job now

CHANNELS 

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Search



November 26, 2021 08:35 AM EST

Updated 12:53 PM

Bioregnum, Cell/Gene Tx

What were Endpoints readers tuning into this year? Here's a look at our 15 most popular reports of the year (so far)

John Carroll

Editor & Founder

At the beginning of this year, I laid out a basic objective for *Endpoints News* as we headed to our 5th anniversary. We've long been doing a fine job covering the breaking news in R&D — if I do say so myself — but we needed to expand our horizons on industry coverage, increase the staff and go much, much deeper when the stories demanded it.

In a phrase: [broader and deeper](#).

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Search

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP

LOG IN



ENDPOINTS
MARKETING **Rx**

November 23, 2021 01:39 PM EST
Updated November 24, 04:08 AM
Pharma, Marketing

MarketingRx roundup: Amgen, Lilly, Biohaven migraine brand recall low, study says; Novartis looks to

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE



ENDPOINTS NEWS

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP

LOG IN

CHANNELS



ENDPOINTS NEWS

BIOPHARMA JOBS

MORE



November 22, 2021 05:00 AM EST

Updated November 24, 02:45 AM

Pharma, Marketing

Name that vaccine: From Comirnaty to Spikevax to Nuvaxovid, Covid-19 shots' brand names remain little-known

Beth Snyder Bulik

Senior Editor

Most people know if they're "Team Pfizer" or "Team Moderna," but few know if they got the Comirnaty or Spikevax Covid-19 vaccine. Those are the brand names of Pfizer and Moderna vaccines, respectively, however they have yet to take hold with consumers, media or even medical professionals.

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE ▼

Troy Wilson, Kura CEO

November 24, 2021 07:01 AM EST

Updated 10:30 AM

R&D, FDA+

UPDATED: FDA hits the red light on an early-stage AML study after a patient dies

John Carroll

CHANNELS ▼

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE 

ENDPOINTS NEWS

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP

LOG IN

ENDPOINTS CAREERS

Executive Director - Data Analysis - Science & Technology

Alexandria Real Estate Equities
Pasadena, CA

VIEW JOB OFFER

post your job now

CHANNELS 

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE

Search



Robert Davis, Merck CEO

November 26, 2021 09:36 AM EST

FDA+

Merck shares slide as response to its oral Covid antiviral plunges on latest update

John Carroll

Editor & Founder

After a second look, Merck says that its big breakthrough on the Covid front doesn't look so good.

The pharma giant updated its data on its oral antiviral molnupiravir on Friday, and said that its drug reduced the rate of hospitalization and death by 30% — a sharp plunge from the 50% rate [reported](#) at the beginning of October during their interim readout.

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE



Emma Walmsley, GlaxoSmithKline CEO (Fang Zhe/Xinhua/Alamy Live News)

November 22, 2021 05:00 PM EST

Updated 05:42 PM

Deals

GlaxoSmithKline places a risky bet on Arrowhead's RNA drug in the failure-strewn NASH field

Kyle Blankenship
Managing Editor

CHANNELS

ENDPOINTS NEWS

BIOPHARMA JOBS

MORE 

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,200+ biopharma pros reading Endpoints daily — and it's free.

SIGN UP

LOG IN

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

LATEST

- All News
- Premium Content
- Don't Miss
- Special
- In Focus

CHANNELS

ENDPOINTS NEWS

[Cell/Gene Tx](#)

[China](#)

[Coronavirus](#)

[Deals](#)

[Discovery](#)

[FDA+](#)

[Financing](#)

[Outsourcing](#)

[Peer Review](#)

[People](#)

[Pharma](#)

[R&D](#)

[Startups](#)

[Weekly](#)

MORE

[Letter to Editors](#)

[IPO Tracker](#)

[Events](#)

[Webinars](#)

[Sponsored Posts](#)

[Advertise](#)

[About Us](#)

[Help](#)

WORK IN BIOTECH

[Endpoints Careers](#)

[Help](#)

[Advertise](#)

[Privacy Policy](#)

[Business Model](#)

© Endpoints Company 2021